Literature DB >> 31081100

Expression of long non-coding RNA MAGI2‑AS3 in human gliomas and its prognostic significance.

X-D Chen1, M-X Zhu, S-J Wang.   

Abstract

OBJECTIVE: It has been confirmed that the dysregulation of long noncoding RNAs (lncRNAs) is associated with various diseases, especially cancer. LncRNA MAGI2 antisense RNA 3 (MAGI2-AS3) has been reported to be involved in the progression of bladder cancer and breast cancer. In this study, we aimed to explore its expression and clinical significance in glioma. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assays were performed to detect the expression levels of MAGI2-AS3 in fresh glioma and matched adjacent normal brain tissue specimens, which were collected from 178 patients. Then the association between MAGI2-AS3 expression and clinical-pathological parameters were further evaluated using the Chi-square test. The overall survival (OS) was analyzed by the log-rank test, and the survival curves were plotted according to Kaplan-Meier. Univariate and multivariate analyses were performed to analyze the prognostic significance of MAGI2-AS3 expression.
RESULTS: We found that the relative expression level of MAGI2-AS3 in glioma tissues was significantly lower than those in adjacent normal brain tissues (p<0.01). Lower MAGI2-AS3 expression was observed to be positively correlated with the World Health Organization (WHO) grade (p=0.031) and KPS score (p=0.003) in glioma patients. The Kaplan-Meier analysis indicated that patients with low MAGI2-AS3 expression levels tended to have worse overall survival than those with high levels of MAGI2-AS3 expression (p=0.0042). In the multivariate analysis, we further observed that MAGI2-AS3 expression in glioma tissues was an independent prognostic factor for overall survival (HR=3.098, 95% CI: 1.289-4.118, p=0.014).
CONCLUSIONS: MAGI2-AS3 expression represents a significant favorable prognostic factor for patients with glioma.

Entities:  

Year:  2019        PMID: 31081100     DOI: 10.26355/eurrev_201904_17710

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  The Involvement of Long Non-Coding RNAs in Glioma: From Early Detection to Immunotherapy.

Authors:  Xiaoben Wu; Lei Yang; Jing Wang; Yingying Hao; Changyin Wang; Zhiming Lu
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

2.  Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma.

Authors:  Priyanka Gokulnath; Tiziana de Cristofaro; Ichcha Manipur; Tina Di Palma; Amata Amy Soriano; Mario Rosario Guarracino; Mariastella Zannini
Journal:  Cancers (Basel)       Date:  2019-12-12       Impact factor: 6.639

3.  MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis.

Authors:  Hua Chang; Xue Zhang; Baixue Li; Xiangkai Meng
Journal:  Cancer Med       Date:  2020-07-18       Impact factor: 4.452

4.  Construction of a long noncoding RNA-based competing endogenous RNA network and prognostic signatures of left- and right-side colon cancer.

Authors:  Ke-Zhi Li; Yi-Xin Yin; Yan-Ping Tang; Long Long; Ming-Zhi Xie; Ji-Lin Li; Ke Ding; Bang-Li Hu
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

5.  Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.

Authors:  Jiarong Cai; Zheng Chen; Xuelian Chen; He Huang; Xia Lin; Bin Miao
Journal:  Biomed Res Int       Date:  2020-09-01       Impact factor: 3.411

6.  Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer.

Authors:  Chong Shen; Yujie Wang; Zhouliang Wu; Shen Gao; Linguo Xie; Yunkai Qie; Yinlei Wang; Zhe Zhang; Dawei Tian; Hailong Hu
Journal:  Oncol Rep       Date:  2020-08-13       Impact factor: 3.906

7.  MAGI2-AS3 rs7783388 polymorphism contributes to colorectal cancer risk through altering the binding affinity of the transcription factor GR to the MAGI2-AS3 promoter.

Authors:  Xi Yang; Shenshen Wu; Xiaobo Li; Ying Yin; Rui Chen
Journal:  J Clin Lab Anal       Date:  2020-06-12       Impact factor: 2.352

8.  Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits.

Authors:  Bryan C Quach; Michael J Bray; Nathan C Gaddis; Mengzhen Liu; Teemu Palviainen; Camelia C Minica; Stephanie Zellers; Richard Sherva; Fazil Aliev; Michael Nothnagel; Kendra A Young; Jesse A Marks; Hannah Young; Megan U Carnes; Yuelong Guo; Alex Waldrop; Nancy Y A Sey; Maria T Landi; Daniel W McNeil; Dmitriy Drichel; Lindsay A Farrer; Christina A Markunas; Jacqueline M Vink; Jouke-Jan Hottenga; William G Iacono; Henry R Kranzler; Nancy L Saccone; Michael C Neale; Pamela Madden; Marcella Rietschel; Mary L Marazita; Matthew McGue; Hyejung Won; Georg Winterer; Richard Grucza; Danielle M Dick; Joel Gelernter; Neil E Caporaso; Timothy B Baker; Dorret I Boomsma; Jaakko Kaprio; John E Hokanson; Scott Vrieze; Laura J Bierut; Eric O Johnson; Dana B Hancock
Journal:  Nat Commun       Date:  2020-11-03       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.